Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7629372 | 0.94 | ALDH1A1 (0.52) | ALDH1A1NPSR1 | |
| SCHEMBL6595306 | 0.90 | ALDH1A1 (0.57) | ALDH1A1NPSR1POLBOPRM1OPRD1 | |
| SCHEMBL7623102 | 0.90 | ALDH1A1 (0.52) | ALDH1A1NPSR1POLBOPRM1OPRD1 | |
| SCHEMBL7621522 | 0.90 | ALDH1A1 (0.52) | ALDH1A1NPSR1POLBOPRM1OPRD1 | |
| SCHEMBL7486755 | 0.89 | ALDH1A1 (0.52) | ALDH1A1NPSR1POLBOPRM1OPRD1 | |
| SCHEMBL7622238 | 0.89 | ALDH1A1 (0.52) | ALDH1A1NPSR1POLBOPRM1OPRD1 | |
| SCHEMBL6598357 | 0.88 | ALDH1A1 (0.51) | ALDH1A1NPSR1 | |
| SCHEMBL7628660 | 0.88 | ALDH1A1 (0.56) | ALDH1A1NPSR1POLBOPRM1OPRD1 | |
| SCHEMBL6592173 | 0.88 | ALDH1A1 (0.59) | ALDH1A1NPSR1POLB | |
| SCHEMBL7626135 | 0.87 | ALDH1A1 (0.50) | ALDH1A1NPSR1OPRM1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| US-6194406-B1 | HISTAMINE RECEPTOR ANTAGONISTS; TACHYKININ RECEPTOR ANTAGONISTS; ASTHMA; BRONCHITIS; INFLAMMATORY BOWEL DISEASES, INCLUDING CROHN'S DISEASE AND ULCERATIVE COLITIS; SEASONAL RHINITIS; SINUSITIS; ANTIALLERGENS; EMETIC AGENTS | AVENTIS PHARMACEUTICALS INC. | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | ALDH1A1 953/4885NPSR1 102/4885POLB 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.